Skip to main content
TipRanks
Go Ultimate75% OFF

Albert David Ltd (ALBERTDAVD) AI Stock Analysis

0 Followers
IN:ALBERTDAVD

Albert David Ltd

(NSE:ALBERTDAVD)

Select Model
Rating:40Underperform
Price Target:INR 746.00â–¼(-1.01% Downside)
Action:reiterated
Date:11/18/26

The score is driven primarily by a severe fundamental downturn: falling revenue, a swing from strong profits to an operating and net loss, halved gross profit, and two straight years of negative operating and free cash flow funded by rising debt. A still-solid equity base and historically low leverage prevent a lower score, but the trend is unfavourable. Technicals are neutral at best - the stock holds above its 200-day average yet trades below the 50-day with negative MACD and mid-range momentum readings. Valuation offers little protection, as the 15.5x P/E reflects earnings that have already evaporated and the 0.63% yield is thin. Without evidence of a margin and cash flow turnaround, this remains a high-risk situation.

Positive Factors
Conservative balance sheetConservative financing reduces balance-sheet risk and gives Albert David greater resilience during periods of weaker earnings. Low leverage can also preserve borrowing capacity and allow management to fund operations or strategic investment without excessive interest or refinancing pressure.
Negative Factors
Profitability deteriorationThe shift from solid profits to a net loss and negative operating profit is a significant deterioration in earnings quality. Persistent operating losses would weaken internal funding capacity, reduce returns on the enlarged equity base, and make recovery dependent on reversing margin pressure.

Albert David Ltd (ALBERTDAVD) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%IN:ALBERTDAVD-2.18%INDA-5.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 4.34B
Dividend Yield
0.66%
Average Volume (3M)
268
Price to Earnings (P/E)
15.1
Beta (1Y)
1.04
Revenue Growth
19.69%
EPS Growth
―
Country
India
Employees
1,476
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Albert David Ltd Business Overview & Revenue Model

Company Description

Albert David Limited is an Indian pharmaceutical company specializing in the production and distribution of a diverse array of medical products. Its offerings encompass pharmaceutical formulations, intravenous solutions, herbal medicines, bulk drug s...

Albert David Ltd Financial Statement Overview

Summary

Fundamentals have deteriorated sharply. Revenue has declined for two consecutive years (₹3.60B in FY2024 to a projected ₹3.34B in FY2026), while net income collapsed from ₹754M to a loss of ₹15M and EBIT turned negative. Gross profit halved from ₹2.3B to ₹1.1B, pointing to structural cost or pricing pressure rather than a temporary setback. Cash flow is the weakest link, with operating cash flow negative for two years and free cash flow at -₹433M and -₹351M, forcing reliance on borrowings. The balance sheet is the only relative cushion: equity has grown to ₹3.92B and leverage remains low in absolute terms, but total debt more than doubled to ₹297M and ROE fell from ~20% to ~4.4%, so even this strength is eroding.

Income Statement

28Negative

Balance Sheet

52Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.64B3.34B3.46B3.60B3.42B3.12B
Gross Profit1.30B1.07B2.29B2.32B2.18B1.95B
EBITDA-2.27M129.20M30.26M1.05B598.68M567.76M
Net Income225.66M-14.95M172.01M754.20M361.75M352.58M
Balance Sheet
Total Assets05.19B5.11B4.98B4.23B4.03B
Cash, Cash Equivalents and Short-Term Investments2.58B2.58B2.44B2.85B2.03B1.75B
Total Debt0297.11M123.17M33.24M53.18M56.62M
Total Liabilities-3.92B1.28B1.19B1.15B1.12B1.23B
Stockholders Equity3.92B3.92B3.92B3.83B3.12B2.79B
Cash Flow
Free Cash Flow-271.21M-350.95M-432.92M346.28M52.78M292.83M
Operating Cash Flow-208.45M-59.83M-284.36M455.02M105.15M403.65M
Investing Cash Flow-46.97M-85.53M233.01M-332.48M-49.95M-396.97M
Financing Cash Flow248.82M144.00M1.10M-82.70M-63.62M-12.59M

Albert David Ltd Technical Analysis

Technical Analysis SentimentNegative
Last Price753.60

Price Trends

50DMA813.62Negative
100DMA784.12Negative
200DMA742.45Positive

Market Momentum

MACD-8.71Negative
RSI39.52Neutral
STOCH11.86Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 753.60 is below the 20-day moving average (MA) of 775.77, below the 50-day MA of 813.62, and above the 200-day MA of 742.45, indicating a neutral trend. The MACD of -8.71 indicates Negative momentum. The RSI at 39.52 is Neutral, neither overbought nor oversold. The STOCH value of 11.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ALBERTDAVD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:IOLCPIN:IOLCP72OutperformINR 55.74B27.42―0.53%26.76%75.41%
IN:APLLTDIN:APLLTD71OutperformINR 205.12B24.33―1.15%19.68%33.03%
IN:GLENMARKIN:GLENMARK66NeutralINR 749.31B51.45―0.19%-0.11%43.72%
IN:IPCALABIN:IPCALAB58NeutralINR 470.33B33.54―0.32%11.99%68.61%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 34.01B9.95――6.44%283.10%
IN:ALBERTDAVDIN:ALBERTDAVD40UnderperformINR 4.30B15.08―0.66%19.69%―

* General Sector Average

Performance Comparison

0%50%100%IN:ALBERTDAVDIN:APLLTDIN:GLENMARKIN:IOLCPIN:IPCALABIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ALBERTDAVD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ALBERTDAVDAlbert David Ltd753.60-29.76-3.80%
IN:APLLTDAlembic Pharmaceuticals Limited1043.55154.7317.41%
IN:GLENMARKGlenmark Pharmaceuticals Limited2655.00811.6844.03%
IN:IOLCPIOL Chemicals & Pharmaceuticals Ltd.189.90100.80113.13%
IN:IPCALABIPCA Laboratories Limited1854.20415.3528.87%
IN:UNICHEMLABUnichem Laboratories Limited483.0515.253.26%

Albert David Ltd Corporate Events

Albert David Board Approves Unaudited Results for September 2026 Period

Nov 12, 2026

Albert David Limited submitted its unaudited financial results for the quarter and half year ended September 30, 2026. The Board approved and took the results on record at its November 12, 2026 meeting, along with the Statutory Auditor’s Limited Revi...

Albert David files SEBI demat compliance certificate for Q2 FY27

Oct 6, 2026

Albert David Ltd has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate, issued by registrar and share transfer agent Mahes...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026